share_log

Lisata Therapeutics Announces US FDA Rare Pediatric Disease Designation Granted To LSTA1 For Treatment Of Osteosarcoma

Benzinga ·  Mar 21 08:02
Lisata Therapeutics Announces US FDA Rare Pediatric Disease Designation Granted To LSTA1 For Treatment Of Osteosarcoma
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment